JPMorgan cuts Xylem to underweight, lowers target to $90
JPMorgan cut its rating on Xylem from neutral to underweight and lowered its price target from $118 to $90.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.